FDA-Approved Sickle Cell Therapies From Bluebird Bio And Vertex Join Medicaid Innovation Program

The Biden-Harris administration has announced an initiative to improve access to gene therapies for sickle cell disease under the Cell and Gene Therapy Access Model. This voluntary model, developed by the Center for Medicare and Medicaid Innovation, seeks to enhance access to these therapies, improve patient outcomes, and reduce healthcare costs by tying payments to treatment efficacy for Medicaid recipients. Also Read: FDA Probes Potential Life-Threatening Blood Cancer Risks Linked To Bluebird Bio’s Skysona Gene Therapy Two drug manufacturers, Bluebird Bio Inc. (NASDAQ: BLUE ) and Vertex Pharmaceuticals.

Back to news